EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

Jingyi Ke, Zi Wang, Zhengyang Guo, Guangshuo Ou, Wei Li

PLOS Genetics · 19.11.2026 · 22 (11) · e1012373

DOI: 10.1371/journal.pgen.1012373 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Genetics, online erschienen am 19.11.2026. Verfasst von Jingyi Ke und 4 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Technologies Research and Development Program, National Natural Science Foundation of China, TsienTang Life Science Development Fund at Tsinghua University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncogenic BRAFV600E mutations drive constitutive MAPK signaling across various cancers; however, resistance to MEK inhibitors such as trametinib undermines clinical benefits, and the mechanisms sustaining MAPK activity under treatment remain unclear. We developed a lin-45(V627E) Caenorhabditis elegans model to mimic oncogenic BRAF signaling and found that these animals exhibited high-dose trametinib resistance, as assessed by brood size. Transcriptomic analysis revealed increased egl-30 expression in worms resistant to high-dose trametinib. Genetic and pharmacological analyses implicated EGL-30/Gαq-PLC-PKC signaling in this high-dose resistance phenotype. In trametinib-resistant A375 melanoma cells, F2RL1 , which encodes the Gαq-coupled GPCR PAR2, was upregulated compared with parental cells. Functional inhibition of PAR2 or downstream Gαq signaling reduced ERK phosphorylation and impaired the viability of trametinib-resistant melanoma cells. Furthermore, combined inhibition of MEK and Gαq-PLC-PKC signaling synergistically suppresses tumor growth and restores trametinib sensitivity in xenograft models. These findings uncover Gαq-associated signaling as a conserved contributor to trametinib resistance and a potential therapeutic vulnerability in BRAF-mutant melanoma.

Förderung

  • Key Technologies Research and Development Program
  • National Natural Science Foundation of China
  • TsienTang Life Science Development Fund at Tsinghua University

Zitieren

APA

Ke, J., Wang, Z., Guo, Z., Ou, G., & Li, W. (2026). GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma. PLOS Genetics, 22(11), e1012373. https://doi.org/10.1371/journal.pgen.1012373

Vancouver

Ke J, Wang Z, Guo Z, Ou G, Li W. GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma. PLOS Genetics. 2026;22(11):e1012373. doi:10.1371/journal.pgen.1012373

BibTeX
@article{Ke2026,
  author = {Ke, Jingyi and Wang, Zi and Guo, Zhengyang and Ou, Guangshuo and Li, Wei},
  title = {GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma},
  journal = {PLOS Genetics},
  year = {2026},
  volume = {22},
  number = {11},
  pages = {e1012373},
  doi = {10.1371/journal.pgen.1012373}
}
Kostenlos starten →